| Active Not Recruiting | Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ova NCT02627443 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, NCT02713386 | NRG Oncology | Phase 1 / Phase 2 |
| Withdrawn | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With NCT03902379 | Rutgers, The State University of New Jersey | N/A |
| Active Not Recruiting | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontl NCT02726997 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, NCT02520154 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary P NCT02659241 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tu NCT02316834 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopia NCT02042430 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Active Not Recruiting | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid T NCT02142803 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopi NCT01970722 | City of Hope Medical Center | Phase 1 |
| Completed | Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, NCT01749397 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previo NCT00719303 | Gynecologic Oncology Group | Phase 3 |
| Completed | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian NCT01504126 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Unknown | Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovar NCT01366183 | Gynecologic Oncology Group | — |
| Unknown | Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, NCT01372787 | Gynecologic Oncology Group | — |
| Active Not Recruiting | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy i NCT01081262 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage NCT01167712 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovar NCT00989651 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Ut NCT00954174 | GOG Foundation | Phase 3 |
| Completed | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epi NCT00951496 | National Cancer Institute (NCI) | Phase 3 |
| Unknown | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian E NCT00108745 | GOG Foundation | Phase 3 |